The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
The acquisition is for an enterprise value of Rs. 218 crores
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated